Taiho Pharmaceutical Co., Ltd.
Quick facts
| Founded | 1963 |
|---|
Marketed products
- Jeselhy · Oncology
Phase 3 pipeline
- Cisplatin (arm B) · Oncology
Cisplatin is a platinum-based chemotherapy agent that forms DNA adducts and crosslinks, preventing DNA replication and triggering cancer cell death. - cyclophosphamide, methotrexate, and fluorouracil
- Gemcitabine plus TS-1 · Oncology
Gemcitabine plus TS-1 is a combination chemotherapy regimen that inhibits DNA synthesis and disrupts nucleotide metabolism to kill rapidly dividing cancer cells. - Placebo [Ambulatory Cohort] only
Placebo has no active pharmacological mechanism; it serves as a control comparator in clinical trials. - S-1 + Cisplatin (arm A) · Oncology
S-1 is an oral fluoropyrimidine prodrug that inhibits thymidylate synthase and other enzymes in nucleotide synthesis, while cisplatin is a platinum-based alkylating agent that cross-links DNA, together producing synergistic cytotoxic effects against cancer cells. - S-1 plus CDDP · Oncology
S-1 plus CDDP is a combination chemotherapy regimen that inhibits thymidylate synthase and causes DNA cross-linking to suppress cancer cell proliferation. - S-1 plus Cisplatin · Oncology
S-1 is a fluoropyrimidine derivative that inhibits thymidylate synthase, while cisplatin is a platinum-based alkylating agent that cross-links DNA, thereby inhibiting DNA replication and transcription. - TAS-118 plus Oxaliplatin · Oncology
TAS-118 is a thymidylate synthase inhibitor, and when combined with oxaliplatin, it targets rapidly dividing cancer cells. - TS-1 and cisplatin · Oncology
TS-1 is a prodrug that is converted into 5-fluorouracil (5-FU) in the body, which is then incorporated into DNA and RNA, interfering with DNA replication and transcription, and cisplatin is a platinum-based chemotherapy drug that works by cross-linking DNA, thereby inhibiting DNA replication and transcription. - UFT (uracil, tegafur) · Oncology
UFT is a combination of uracil and tegafur that inhibits thymidylate synthase to block DNA synthesis and induce cancer cell death.
Phase 2 pipeline
- CPT-11, 5-FU and l-LV · Oncology
Topoisomerase I inhibitor - CPT-11 and TS-1
- S-1, Bevacizumab
- S-1, Irinotecan, Bevacizumab
- TAC-302
- TAS-205
- TAS5315 Dose 1
- TAS5315 high dose
- TAS5315 low dose
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: